Newbury Pharmaceuticals

Newbury Pharmaceuticals Secures Generic Approval for Azelastine + Fluticasone nasal spray

Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Azelastine + Fluticasone nasal spray in Norway as the first country in a Nordic registration procedure. Approvals in Sweden, Finland and Denmark are expected to follow upon finalized national reviews.

Azelastine and fluticasone combination nasal spray is used to treat an itchy or runny nose, sneezing, or other symptoms caused by seasonal hay fever (allergic rhinitis). Azelastine + Fluticasone Newbury is a generic version of Dymista nasal spray. Dymista achieved sales exceeding €21 million in the Nordics, as reported by DLMI. 

“The successful approval of Azelastine + Fluticasone Newbury highlights Newbury's capability to offer a diverse and comprehensive portfolio and it is also Newbury’s first marketing authorization in Finland which opens up a new market for the company” says Mr Lars Minor CEO of Newbury
Datum 2025-01-15, kl 14:00
Källa MFN
Alla Aktier tipsar: Har du redan ett konto på Avanza? Varför inte skapa ett på Nordnet också och jämföra funktioner, courtage mm. Det tar inte lång tid, du fixar det direkt här med BankID
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet